Key result
Niclosamide, an FDA-approved anthelminthic drug, exhibits broad antiviral activity against various viruses with nanomolar to micromolar potency, indicating potential for treating COVID-19.
Why the study?
The outbreak of COVID-19 highlighted an urgent need for therapeutics, prompting investigation into the repurposing of niclosamide as a broad-spectrum antiviral agent.
Does niclosamide have potential as an antiviral agent for the treatment of COVID-19 and other viral infections?
Does niclosamide have potential as an antiviral agent for the treatment of COVID-19 and other viral infections?
Answers are grounded in this paper and cite their sources.
Niclosamide demonstrates broad-spectrum antiviral activity and may have potential clinical use in the treatment of COVID-19.
The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2020) conducted a review in Viral infections (including COVID-19). Niclosamide was evaluated. Niclosamide, an FDA-approved anthelminthic drug, exhibits broad antiviral activity against various viruses with nanomolar to micromolar potency, indicating potential for treating COVID-19.
Synapse has enriched 10 related papers. Consider them for comparative context: